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A B S T R A C T
Background
Treatment of cancer is increasingly effective but is associated with short and long term side effects. Oral and gastrointestinal side effects,
including oral candidiasis, remain a major source of illness despite the use of a variety of agents to treat them.
Objectives
To assess the effectiveness of interventions for the treatment of oral candidiasis for patients with cancer receiving chemotherapy or
radiotherapy or both.
Search methods
Computerised searches of Cochrane Oral Health Group and PaPaS Trials Registers (to 1 June 2010), CENTRAL via the Cochrane
Library (Issue 2, 2010, 1 June 2010), MEDLINE via OVID (1 June 2010), EMBASE via OVID (1 June 2010), CINAHL via EBSCO
(1 June 2010), CANCERLIT via PubMed (1 June 2010), OpenSIGLE (1 June 2010) and LILACS via Virtual Health Library (1 June
2010) were undertaken.
Reference lists from relevant articles were searched and the authors of eligible trials were contacted to identify trials and obtain additional
information.
Selection criteria
All randomised controlled trials comparing agents prescribed to treat oral candidiasis in people receiving chemotherapy or radiotherapy
for cancer. The outcomes were eradication of oral candidiasis, dysphagia, systemic infection, amount of analgesia, length of hospitali-
sation, cost and patient quality of life.
Data collection and analysis
Data were independently extracted, in duplicate, by two review authors. Trial authors were contacted for details of randomisation and
withdrawals and a quality assessment was carried out. Risk ratios (RR) were calculated using fixed-effect models.
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Main results
Ten trials involving 940 patients, satisfied the inclusion criteria and are included in this review. Drugs absorbed from the gastrointestinal
(GI) tract were beneficial in eradication of oral candidiasis compared with drugs not absorbed from the GI tract (three trials: RR =
1.29, 95% confidence interval (CI) 1.09 to 1.52), however there was significant heterogeneity. A drug absorbed from the GI tract,
ketoconazole, was more beneficial than placebo in eradicating oral candidiasis (one trial: RR = 3.61, 95%CI 1.47 to 8.88). Clotrimazole,
at a higher dose of 50 mg was more effective than a lower 10 mg dose in eradicating oral candidiasis, when assessed mycologically (one
trial: RR = 2.00, 95% CI 1.11 to 3.60). Only one of the ten trials was assessed as at low risk of bias.
Authors’ conclusions
There is insufficient evidence to claim or refute a benefit for any antifungal agent in treating candidiasis. Further well designed, placebo-
controlled trials assessing the effectiveness of old and new interventions for treating oral candidiasis are needed. Clinicians need to
make a decision on whether to prevent or treat oral candidiasis in patients receiving treatment for cancer.
P L A I N L A N G U A G E S U M M A R Y
Interventions for treating oral candidiasis for patients with cancer receiving treatment
Cancer treatment can lead to severe fungal infections (candidiasis, called thrush) in the mouth. This can cause pain, difficulties in eating
and longer hospital stays. Infection can sometimes spread through the body and become life-threatening. Different drugs are used to
try and relieve candidiasis. There is insufficient evidence that any of the antifungal drugs may cure fungal infections in the mouth for
people with cancer and more research is needed.
B A C K G R O U N D
Treatment of solid malignant tumours and the leukemias with
cytotoxic chemotherapy or radiotherapy or both is becoming in-
creasingly more effective but it is associated with short and long
term side effects. Among the clinically important acute side effects
is the disruption in the function and integrity of the oral mucosa.
The consequences of this include severe ulceration (mucositis) and
fungal infection of themouth (oral candidiasis). These disease and
treatment induced complications may also produce oral discom-
fort and pain, poor nutrition, delays in drug administration, in-
creased hospital stays and costs and in some patients life threaten-
ing infection (septicaemia).
Patients with cancer are advised to maintain oral hygiene. De-
pending on the cancer centre, the patient’s age and the expected
toxicity of their treatment protocol, additional agents may be pro-
vided to prevent oral complications. Nevertheless, oral complica-
tions remain a major source of illness despite the use of a variety
of agents to prevent them. A recent Cochrane review looked at
the use of oral and topical prophylactic agents for the prevention
of oral candidiasis in patients with cancer treated by chemother-
apy (Clarkson 2007a). The review concluded that there is strong
evidence, from randomised controlled trials, that drugs absorbed
or partially absorbed from the gastrointestinal (GI) tract prevent
oral candidiasis in patients receiving treatment for cancer. There is
also evidence that these drugs are significantly better at preventing
oral candidiasis than drugs not absorbed from the GI tract. This
present review follows on from this and looks at the treatment of
overt oral candidiasis in patients receiving treatment for cancer.
This review is one in a series of four Cochrane reviews looking
at the prevention and treatment of both oral candidiasis and oral
mucositis (Clarkson 2007a; Clarkson 2007b;Worthington 2007).
O B J E C T I V E S
To assess the effectiveness of interventions (which may include
placebo or no treatment) for the treatment of oral candidiasis for
patients with cancer, receiving chemotherapy or radiotherapy or
both.
The following primary null hypothesis was tested for comparisons
between groups treated for oral candidiasis:
There is no difference in the proportion of patients without oral
candidiasis after treatment.
The primary outcomes were therefore:
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• Eradication of candidiasis
• Improvement of candidiasis.
In this review we proposed to address the hypothesis of no differ-
ence between groups treated for oral candidiasis for the following
secondary outcomes if data were available from studies which in-
cluded a primary outcome:
• Relief of pain
• Amount of analgesia
• Relief of dysphagia
• Incidence of systemic infection
• Days stay in hospital
• Cost of oral care
• Patient quality of life.
The following subgroup analyses were proposed:
• Cancer type (leukaemia, solid cancer and mixed)
• Cancer treatment type
• Age group (children, adults, children and adults).
M E T H O D S
Criteria for considering studies for this review
Types of studies
Only randomised controlled trials were eligible for inclusion in
this review.
Types of participants
Anyone with cancer who received chemotherapy or radiotherapy
or both and had overt oral candidiasis.
Types of interventions
Active agents: any antifungal intervention for the treatment of oral
candidiasis.
Control: may be placebo or no treatment, or another active inter-
vention.
Types of outcome measures
Primary outcome:
• Oral candidiasis (absent or present)
Secondary outcomes:
• Relief of pain
• Amount of analgesia
• Relief of dysphagia
• Incidence of systemic infection
• Days stay in hospital
• Cost of oral care
• Patient quality of life.
Search methods for identification of studies
This review is part of a series of four reviews on the prevention
and treatment of oral candidiasis and oral mucositis in patients
with cancer, and the same search strategies were used for all four
reviews.
The searches attempted to identify all relevant trials irrespective
of language. Papers not in English were translated by members of
The Cochrane Collaboration.
Electronic searches:
The following databases were searched:
Cochrane Oral Health Group Trials Register (whole database, to
1 June 2010) (see Appendix 1)
Cochrane Pain, Palliative and Supportive Care (PaPaS) Group Tri-
als Register (whole database, to 1 June 2010) (see Appendix 1)
Cochrane Central Register of ControlledTrials (CENTRAL) (The
Cochrane Library 2010, Issue 2; searches conducted 1 June 2010)
(see Appendix 2)
MEDLINE via OVID (1950 to 1 June 2010) (see Appendix 3)
EMBASE via OVID (1980 to 1 June 2010) (see Appendix 4)
CINAHL via EBSCO (1980 to 1 June 2010) (see Appendix 5)
CANCERLIT via PubMed (1950 to 1 June 2010) (see Appendix
6)
OpenSIGLE (1980 to 1 June 2010) (see Appendix 7)
LILACS via the Virtual Health Library (1980 to 1 June 2010) (see
Appendix 8)
Sensitive search strategies were developed for each database us-
ing a combination of free text and MeSH terms. The MEDLINE
and CANCERLIT subject searches were conducted with the ad-
dition of the Cochrane Highly Sensitive Search Strategy (CHSSS)
for identifying randomized trials in MEDLINE: sensitivity maximis-
ing version (2009 revision) as referenced in Chapter 6.4.11.1 and
detailed in boxes 6.4.a and 6.4c of the Cochrane Handbook for
Systematic Reviews of Interventions Version 5.0.2 (Higgins 2009).
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Filters developed by the Cochrane Oral Health Group for iden-
tifying randomised controlled trials were used for the searches of
EMBASE and CINAHL. The LILACS subject search was linked
to the Brazilian Cochrane Center search strategy for identifying
randomised controlled trials in LILACs.
Searching other resources:
Only handsearching carried out by The Cochrane Collaboration
is included in the search (see master list www.cochrane.org).
The controlled trials database (www.controlled-trials.com) was
also searched to identify ongoing and completed trials and to con-
tact trialists for further information about these trials.
The reference list of related review articles and all articles obtained
were checked for further trials. Authors of trial reports and spe-
cialists in the field known to the review authors were written to
concerning further published and unpublished trials.
The review will be updated every 2 years using the Cochrane
OralHealth Group Trials Register, CENTRAL,MEDLINE, EM-
BASE, CINAHL, CANCERLIT and LILACS. OpenSIGLE is no
longer being updated and will not be searched for future updates
of this review.
Data collection and analysis
Selection of studies
The titles and abstracts (when available) of all reports identified
through the searches were scanned by two review authors (Jan
Clarkson (JC) and Helen Worthington (HW)). Full reports were
obtained for trials appearing to meet the inclusion criteria or for
which there was insufficient information in the title and abstract
to make a clear decision. The full reports obtained from all the
electronic and other methods of searching were assessed indepen-
dently, in duplicate, by two review authors to establish whether
the trials met the inclusion criteria or not. Disagreements were
resolved by discussion.
Data extraction and management
Data were extracted by two review authors independently using
specially designed data extraction forms. The characteristics of the
trial participants, interventions and outcomes for the included
trials are presented in the study tables. Candidiasis was recorded
as absent or present, and data for both clinical and mycological
assessments were extracted. The duration of trials was recorded
along with interim assessments and a decision made about which
to use to maximise commonality. We also recorded the country
where the trial was conducted, which year it was conducted and
whether a dentist was involved in the investigation. Trial authors
were contacted for clarification or for further information.
Assessment of risk of bias in included studies
The assessment of risk of bias for included trials was undertaken
independently and in duplicate by two review authors. Studies
were analysed for the following to assess validity as a threshold for
inclusion of the studies, which is described as one of the options
in the Cochrane Handbook for Systematic Reviews of Interventions
Version 5.0.2 (Higgins 2009) on the following individual quality
criteria:
• Adequate sequence generation: Yes, No, Unclear
• Allocation concealment: Yes, No, Unclear
• Blinding of participants and carers: Yes, No, Unclear
• Blinidng of outcome assessors: Yes, No, Unclear
• Incomplete outcome data addressed: Yes, No, Unclear
• Free of selective outcome reporting: Yes, No, Unclear
• Free of other biases: Yes, No, Unclear
’Yes’ indicates a low risk of bias, ’No’ indicates high risk of bias
and ’Unclear’ indicates either lack of information or uncertainty
over the potential for bias. A risk of bias table was completed for
each included study. Results are presented graphically by study
(see Figure 1) and by domain over all studies (Figure 2) .
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Figure 1. Methodological quality summary: review authors’ judgements about each methodological quality
item for each included study.
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Figure 2. Methodological quality graph: review authors’ judgements about each methodological quality
item presented as percentages across all included studies.
Risk of bias was assessed for each study. Studies were considered
to be at low risk of bias if there was adequate concealment of
allocation, blinded outcome assessment and information on the
reason for withdrawal provided by trial group. If one of these
criteria was not met a study would be considered at moderate risk
of bias, otherwise at high risk of bias.
Measure of treatment effect
For dichotomous outcomes, the estimates of effect of an interven-
tion were expressed as risk ratios together with 95% confidence in-
tervals. For continuous outcomes mean differences together with
95% confidence intervals were used.
Dealing with missing data
Intention-to-treat analysis was to be conducted where possible.
Methods outlined in the handbook (Higgins 2009) were used to
impute missing standard deviations if these could not be obtained
from trial authors.
Assessment of heterogeneity
We planned to investigate clinical heterogeneity by examining the
different cancer types and age groups, however there were insuffi-
cient trials looking at the same intervention to undertake this.
Assessment of reporting biases
We tabulated all the outcomes considered here.
Data synthesis
Meta-analyses were done only with studies of similar comparisons.
Risk ratios were combined for dichotomous data using random-
effects models (fixed-effect models used if less than 3 studies in
meta-analysis).
Subgroup analysis and investigation of heterogeneity
It was planned to undertake a sensitivity analysis to examine the
effect of concealed allocation and blind outcome assessment on the
overall estimates of effect. However there were insufficient trials
to undertake this.
We proposed a priori to conduct subgroup analyses for different
cancer types (solid, leukaemia andmixed), different types of cancer
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treatment (chemotherapy, radiotherapy) and age groups (children,
adults and mixed). There were insufficient trials by intervention
type to undertake this.
The significance of any discrepancies in the estimates of the treat-
ment effects from the different trials was assessed by means of
Cochran’s test for heterogeneity and quantified by I2 statistics.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies.
Results of the search
The search was conducted for the four similar reviews in this series
(Clarkson 2007a; Clarkson 2007b; Worthington 2007) and has
now been repeated seven times since 1999 for different updates.
The most recent searches in October 2008, August 2009, January
2010 and June 2010 identified 1924, 621, 394 and 294 records
respectively. Following screening of all three databases 125 po-
tential trials were identified for the four reviews. There was only
one further trial to be included in this review update (Bensadoun
2008) and one further study to be excluded (Yamaguchi 2006).
Included studies
SeeCharacteristics of included studies table for further details. One
included study included episodes (n = 60) rather than patients (n
= 56), but as these numbers were similar we decided to include
the study.
Setting
Of the 10 included trials, four were conducted in USA (Flynn
1995; Hughes 1983; Shechtman 1984; Yap 1979) and six in Eu-
rope (Bensadoun 2008; Finlay 1996; Meunier 1990a; Meunier
1990b; Oude 2004; Studena 1995). Six of the trials received exter-
nal funding, three obtained government funding andfive acknowl-
edged assistance from the pharmaceutical industry. The providers
and assessors of the treatments were mainly medical staff although
one of the trials involved a dentist (Finlay 1996). None of the trials
involved the patients in the outcome measurement.
Participants
The results of the 10 trials included in the review are based on 940
patients. The range of patients was from 6 to 141 per treatment
or control group.
Six of the 10 trials recruited only adult patients with cancer, one
included both adults and children (Hughes 1983), one included
only children (Flynn 1995) and in two trials the age of the patients
was unclear (Meunier 1990b; Shechtman 1984). The type of can-
cer being treated was a combination of leukemias and solid tu-
mours in seven trials (Flynn 1995; Hughes 1983; Meunier 1990a;
Meunier 1990b; Oude 2004; Shechtman 1984; Studena 1995),
head and neck cancer in two trials (Bensadoun 2008; Finlay 1996),
and children with unspecified malignancies in the remaining trial
(Flynn 1995). Little information was provided on the cancer treat-
ment regimens received by patients in the trials. In one trial only
radiotherapy was used (Finlay 1996), one trial used both cyto-
toxic chemotherapy and radiotherapy (Oude 2004) and for one
trial information was provided for individual patients regarding
the use of steroids and antibiotics in addition to chemotherapy
(Shechtman 1984). The diagnosis of oral candidiasis at entry into
the trial was usually a combination of both clinical and mycolog-
ical diagnosis. However in two trials only clinical diagnosis was
used (Finlay 1996; Studena 1995).
Interventions
All of the 10 trials provided a clear description of the interventions
including the dose and method of administration for both the test
and control groups. In only two trials was a comparison made with
a placebo (Hughes 1983; Shechtman 1984). The majority of trials
(six) compared different test agents with varying doses, frequency
and duration of use. Two trials compared different doses of a test
agent used at the same frequency and duration (Bensadoun 2008;
Yap 1979).
The interventions for the 10 trials assessing the treatment of oral
candidiasis were categorised according to the degree of absorption
from the gastrointestinal (GI) tract.
Absorbed from the GI tract:
• fluconazole (Finlay 1996; Flynn 1995; Meunier 1990a;
Oude 2004; Studena 1995)
• ketoconazole (Hughes 1983; Meunier 1990a; Meunier
1990b)
• itraconazole (Oude 2004; Studena 1995).
Partially absorbed from the GI tract:
• clotrimazole (Shechtman 1984; Yap 1979).
• miconazole (Bensadoun 2008)
Not absorbed from the GI tract:
• amphotericin B (Finlay 1996)
• nystatin (Flynn 1995; Meunier 1990b).
Outcomes
There was variation between the trials in the assessment of oral
candidiasis. All trials reported both a clinical and microbiologi-
cal outcome of oral candidiasis. All trials used the dichotomous
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clinical outcome ’eradicated’ verus ’not eradicated’. In addition
two trials (Finlay 1996; Flynn 1995) compared the severity before
and after treatment using a 4-point scoring system. For three trials
(Meunier 1990b; Studena 1995; Yap 1979) the method of assess-
ment was not given. Mycological assessments were based on cul-
tures rather than smears in all trials and the dichotomous classifi-
cation of eradicated or not could be obtained from all the 10 trials.
Only in three trials were outcome measures of pain or dysphagia
collected (Bensadoun 2008; Flynn 1995; Shechtman 1984) and
only three reported side effects (Bensadoun 2008; Flynn 1995;
Oude 2004).
Excluded Studies
See Characteristics of excluded studies table for further details.
Seventeen of the apparently eligible studies were excluded: four
were not randomised controlled trials (Holst 1984; Jorgensen
2006; Urabe 1990; Walsh 2002); nine did not have just oral can-
didiasis for entry into the study (Anaissie 1996; Benhamou 1991;
Bourhis 2004; Fleming 2001; Lake 1996; Lefebvre 2002; Subira
2004; Verweij 1994; Walsh 2004); in one study the data were
presented in terms of episodes not patients (Kostiala 1982); two
trials were excluded as the data were not presented in an accessible
form (Conrad 1990; Domenge 1999); and one study conducted
in Japan included patients who were not receiving treatment for
cancer (Yamaguchi 2006).
Risk of bias in included studies
The kappa score between the two raters was one for each item
assessed. Letters were sent to authors of the trials and only one
replied (Finlay 1996), the information supplied changed the con-
cealment of randomisation from unclear to adequate, and clarified
the withdrawals.
One study was assessed as at low risk of bias (Meunier 1990a).The
risk of bias assessment is summarised overall and for each trial in
Figure 1 and Figure 2.
Adequate sequence generation
Adequate sequence generation was observed in four trials (40%),
where a clear statement of the method of randomisation was re-
ported. In the remainder of trials a judgment of ’unclear’ was given
as reporting lacked description with such statements as ’were ran-
domised’ or ’were stratified’ appearing most commonly.
Allocation
Adequate allocation concealment was observed in the same four
trials as above (40%). The remainder failed to indicate whether the
generated randomisation sequence was concealed from individuals
involved in the enrolment and assignment of participants.
Blinding
In four trials (40%) participants and carers were blinded to the
allocated intervention. This was not done for the remaining six
trials. Blinding of outcome assessors was adequate for five trials
(50%), four being unclear and one not blinded.
Incomplete outcome data
In six trials (60%), incomplete outcome data was assessed as ade-
quate. In the remaining four trials it was unclear which group the
patients who were excluded for specific reasons belonged to.
Selective reporting
We consider all trials to be free of selective reporting as the primary
outcomes were included in all.
Other potential sources of bias
This was unclear in eight trials and assessed as ’no’ in two (Flynn
1995; Yap 1979) due to there being a unit of analysis problemwith
episodes rather than patients being used for the analysis. As the
number of episodes was similar to the number of patients in both
(60 and 56 in Flynn 1995; 186 and 180 in Yap 1979), episodes
were used in the data analysis.
Effects of interventions
Comparison 1, Outcome 1.1 - Clinical: eradication of
oral candidiasis
One of the two placebo controlled trials found a significant benefit
(risk ratio (RR) = 3.61, 95% confidence interval (CI) 1.47 to 8.88)
for patients taking the absorbeddrug ketoconazole (Hughes 1983).
In the other placebo controlled trial on the partially absorbed drug,
clotrimazole, no benefit was demonstrated (Shechtman 1984).
Three trials compared different types of absorbed drugs with
each other and they failed to demonstrate a benefit of one drug
against another: one trial compared fluconazole with ketoconazole
(Meunier 1990a); two trials fluconazole versus itraconazole (Oude
2004; Studena 1995).
Three trials compared absorbed drugs (ketoconazole or flucona-
zole) with drugs not absorbed (nystatin or amphotericin B). Two
of these trials demonstrated a significant clinical benefit of the
absorbed drug fluconazole over the non-absorbed drug nystatin
(Finlay 1996; Flynn 1995), and the meta analysis found a benefit
for the absorbed drugs over the non-absorbed drugs (RR = 1.29,
95% CI fixed 1.09 to 1.52; Chi2 for heterogeneity P = 0.01).
However there was substantial heterogeneity between the three
trials with I2 = 78%.
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One trial compared different doses of a partially absorbed drug,
clotrimazole, and failed to find a significant difference (Yap 1979)
(RR = 1.00, 95% CI 0.90 to 1.11).
A further trial compared the partially absorbed drug miconazole
at different doses as a tablet and gel and found no statistically
significant difference in eradication of candidiasis (Bensadoun
2008).
Comparison 1, Outcome 1.2 - Mycological:
eradication of oral candidiasis
There were some differences between the results for the mycologi-
cal assessments compared with those from the clinical assessment.
Despite a significant clinical improvement there was no statisti-
cally significant difference in mycological eradication between an
absorbed drug ketoconazole and placebo (Hughes 1983). How-
ever, there was evidence of different eradication rates with different
absorbed drugs and a statistically significant benefit was found for
fluconazole over itraconazole (RR = 1.17, 95% CI 1.04 to 1.33;
Chi2 for heterogeneity P = 0.30). In agreement with the clinical
assessment there was a statistically significant difference in terms
of a benefit for absorbed drugs compared to not absorbed drugs
(RR = 1.82, 95% CI 1.28 to 2.57; Chi2 for heterogeneity P =
0.001). One further trial (Yap 1979) demonstrated that 50 mg
of the partially absorbed drug clotrimazole eradicated more cases
than the lower dose of 10 mg (RR = 2.00, 95% CI 1.11 to 3.60).
None of the studies reported: relief of pain, relief of dysphagia,
incidence of systemic infection, amount of analgesia, days stay in
hospital, cost of oral care, patient quality of life.
D I S C U S S I O N
Whilst we have been able to achieve our objective in evaluating the
effectiveness of interventions to treat oral candidiasis, there were
insufficient trials to make strong recommendations for patient
care. The generalisability of the results is difficult to comment on
as reporting of the types of cancer and details of treatment was
unclear and few trials included children.
There were only two trials that compared the treatment of candidi-
asis using an active drug with a placebo. There was some evidence,
based on one trial, that ketoconazole is effective, but there is a need
for more trials that include a placebo group. The risk of hepato-
toxicity with prolonged use of ketoconazole could influence treat-
ment decisions and the UKCommittee on Safety ofMedicines has
recommended that prescibers should weigh up the potential ben-
efits against the risk of liver damage, and should carefully monitor
patients both clinically and biochemically (BNF 2009).
There is evidence that absorbed drugs are more effective than
drugs not absorbed from the gastrointestinal tract. There was no
difference found in either trial comparing two absorbed drugs,
and there was an indication that a higher dose of clotrimazole was
more effective than a lower dose, although this was only found
for the mycological assessment. There were no trials comparing
partially absorbed drugs with either absorbed drugs or drugs not
absorbed.
The findings from this review are disappointing as there were only
10 trials including 940 patients, 69 of whom were included in
the two trials with placebo control groups. This is far fewer than
the 28 trials with 4226 patients included in the prevention review
(Clarkson 2007a).
There was limited consistency between trials on the clinical diag-
nosis of oral candidiasis and there was also little reported in terms
of relief of pain, relief of dysphagia, incidence of systemic infec-
tion, amount of analgesia, days stay in hospital, cost of oral care
and patient quality of life. It is therefore difficult to comment on
the importance of these patient based outcomes, although they are
frequently cited as the justification for conducting trials.
It is not possible to assess whether there was any evidence of pub-
lication bias however, with few trials and patients, this could be a
major problem.
For patients being treated for cancer the clinical dilemma is
whether to prevent or treat oral candidiasis. The findings from the
prevention review would suggest that if the incidence of oral can-
didiasis for a patient subgroup is likely to be high then a drug ab-
sorbed or partially absorbed from the gastrointestinal tract should
be prescribed at the start of cancer treatment. The incidence of
oral candidiasis is variable and depends on the nature of the un-
derlying disease and the intensity of treatment. For absorbed drugs
in populations with an incidence of 20% (mid range of results in
control groups), the number needed to treat (NNT) to prevent
one extra case of oral candidiasis was 9 (95% confidence interval
7 to 13) (Clarkson 2007a).
The findings of this review should be considered in the context of
the general medical management of patients with cancer. A review
investigating the routine use of antifungal therapy in cancer pa-
tients did not find an effect on mortality and only a modest effect
on systemic fungal invasion (Gotzsche 2002). The authors ques-
tioned the current widespread practice of prophylactic antifungal
therapy and this finding should be considered when interpreting
the results of this review where we are specifically looking at oral
outcomes.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Clinicians need to make a decision on whether to prevent or treat
oral candidiasis in patients receiving treatment for cancer. The ev-
idence on which drug should be prescribed is weak and unreliable.
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Implications for research
There is a need for more well designed trials that compare the ef-
fectiveness of drugs absorbed, partially absorbed or not absorbed
from the gastrointestinal tractwith a placebo control. These should
be conducted before comparing specific agents with each other.
The limited evidence of effectiveness of current therapies, com-
bined with side-effects profiles of those agents with proven effi-
cacy suggest that new interventions for treating oral candidiasis
are needed.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Bensadoun 2008
Methods Randomised, parallel group multicentre single blind study conducted in France, Tunsia and
Morocco. Patients and carers not blinded. Primary outcome assessment made by blinded
assessor.No evidence of funding apart fromone collaborator is a consultant for pharmaceutical
company who produced the tablets. Patients were recruited from May 2002 until June 2004
Participants Adults with head and neck cancer. 306 patients randomised, 154 to miconazole tablet and
152 to miconazole gel. 6 patients in each group had no treatment, analysis conducted on 141
patient in each group. OP confirmed by direct mycological examination (culture)
Interventions 2 groups: miconazole tablet Lauriad 50 mg MBT (kept in mouth as long as possible) or 500
mg miconazole gel MOG (applied to gums) once daily for 14 days
Outcomes Primary outcome success at day 14 (clinical eradication) and partial response was defined as
improvement by 2 points on Murray Scoring Scale compared with score at baseline. Assess-
ment made at 2, 6, 20 days, unclear which presented
Secondary endpoint was success at day 7. Improvement in clinical symptoms, mycological
cure (culture), recurrence rate and safety also reported
Notes Modified intention-to-treat analysis - all randomised patients who received at least 1 treatment
dose and had efficacy evaluation after randomisation.Non-inferiority statistical approach used
Authors contacted about assessor blinding.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: “patients were randomised”.
Allocation concealment? Unclear Not reported.
Blinding of participants and carers? No Comment: Tablet versus gel.
Blinding of outcome assessors? Unclear Quote: “An amendment introduced a blind
assessment of the primary criterionperformed
in each investigational centre by an indepen-
dent healthcare member who was unaware of
the study drug allocated to each patient. It
was implemented after the inclusion of 59 pa-
tients”
Comment: lack of clarity about how this af-
fected the results
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Bensadoun 2008 (Continued)
Incomplete outcome data addressed? Unclear Comment: Figure 1 provides clear description
of patients for data analysis. Twopatients were
given the wrong intervention, 6 in each group
did not receive treatment and 6 did not have
an outcome assessment. Numbers do not add
up and true intention to treat analysis was not
undertaken
Free of selective reporting? Yes Comment: Both clinical and mycological as-
sessment reported and other secondary out-
comes
Free of other biases? Unclear One author is consultant for pharmaceutical
company who produced tablets for study
Finlay 1996
Methods Randomised, parallel group study conducted in Scotland. The patients were not blinded.
Information on withdrawals clarified by letter. Nomention of funding but possible university
funding. No dates for recruitment period
Participants Adults with head and neck cancer. 77 enrolled, 73 completed.
Interventions 2 groups. Fluconazole 50 mg daily for 7 days. Amphotericin B 10 mg lozenge sucked for 14
days
Outcomes Clinical and mycological eradication (culture). Assessment made at 2, 6, 20 days, unclear
which presented
Notes Communicating with authors changed randomisation assessment from Unclear to Yes (low
risk of bias)
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Comment: Changed after clarification by au-
thors.
Allocation concealment? Yes Comment: Changed after clarification by au-
thors.
Blinding of participants and carers? No Comment: Tablet (7 days) versus lozenge (14
days).
Blinding of outcome assessors? Unclear Comment: Unclear for clinical assessment
and mycological assessment
14Interventions for treating oral candidiasis for patients with cancer receiving treatment (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Finlay 1996 (Continued)
Incomplete outcome data addressed? Yes Comment: Clarified by authors.
Free of selective reporting? Yes Comment: Clinical and mycological eradica-
tion.
Free of other biases? Unclear No information on funding.
Flynn 1995
Methods Randomised, multicentre, parallel group study conducted in USA. Patient, carer not blind,
assessor blind. Clear information on withdrawals given. Pfizer provided the drugs but no
funding mentioned. No dates for recruitment period
Participants Children with malignancies and immunocompromised including HIV (data presented sepa-
rately). 186 enrolled, 182 received drugs, 92 (cancer patients) completed
Interventions 2 groups. Fluconazole 4mg/kg suspension day 1 then 2mg/day.Nystatin 4mlUSP suspension
4 times daily- swished in mouth and swallowed. Both for 14 days in total
Outcomes Clinical and mycological eradication (culture). Assessment at 7 days or later
Notes Study also included children with HIV, but data were presented separately.
The dose of fluconazole was changed 1/4 way into study to 2 mg/kg day 1, then 3 mg/kg
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Quote: “....patients were randomly assigned
to receive....A computer generated random
number code was supplied to each centre by
Pfizer Central Research”
Allocation concealment? Yes Quote: “The randomisation code was held by
the pharmacist; neither patient nor physician
had knowledge of the category of assignment
before enrolment”
Blinding of participants and carers? No Comment: Drugs given at different frequen-
cies.
Blinding of outcome assessors? Yes Quote: “All clinical assessments were per-
formed by investigators unaware of the sub-
jects treatment regime”
Incomplete outcome data addressed? Yes Comment: Clear explanation of withdrawals
by intervention but not for cancer patients as
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Flynn 1995 (Continued)
separate group
Free of selective reporting? Yes Comment: Clinical and mycological eradica-
tion (culture).
Free of other biases? No 6 patients were re-enrolled and treated as new
patients - lack of independence of data. No
reference to funding although Pfizer provided
drug
Hughes 1983
Methods Randomised, parallel group study conducted inUSA. Patient, carer and assessor blind.Unclear
information on withdrawals given. Pharmaceutical company provided the tablets but no other
information about funding. No dates for recruitment period
Participants Children and adults with mixed cancer. 64 enrolled, 56 completed
Interventions 2 groups, placebo versus ketoconazole. 200 mg twice/day. 2 weeks duration
Outcomes Clinical and mycological eradication (culture). Assessment made at day 14
Notes
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: “Randomised in a double blind
placebo controlled study”
Allocation concealment? Unclear Comment: Drug supplied by pharmaceutical
company but concealment still unclear
Blinding of participants and carers? Yes Quote: “Randomised in a double blind
placebo controlled study”
Blinding of outcome assessors? Yes Quote: “Randomised in a double blind
placebo controlled study”
Incomplete outcome data addressed? Unclear 8 patients (12%) withdrawn 5 for noncom-
pliance and 3 by request, but unclear which
group
Free of selective reporting? Yes Comment: Clinical and mycological eradica-
tion (culture).
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Hughes 1983 (Continued)
Free of other biases? Unclear No information on funding except being
given drug by pharmaceutical company
Meunier 1990a
Methods Randomised, parallel group study conducted in Belgium. Patient, carer, assessor blind. No
clear information on withdrawals given. No information on funding except all study drugs
supplied by Pfizer. No dates for recruitment period
Participants Adults with mixed cancer. 40 patients enrolled, 37 completed
Interventions 2 groups. Ketoconazole 2 x 200 mg, once/day. Fluconazole 2 x 250 mg/day. Duration of
therapy from 4 to 27 days, median 14 days
Outcomes Clinical eradication, and improvement. Assessment made at days 4 to 27. Microbiological
eradication of initial pathogen (culture)
Notes
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Quote: “Randomisation chart”.
Allocation concealment? Yes Quote: “All study drugs were supplied by
Pfizer and were administered in identical cap-
sules”
Blinding of participants and carers? Yes Quote: “All study drugs were supplied by
Pfizer and were administered as identical cap-
sules”
Blinding of outcome assessors? Yes Quote: “....double-blind”.
Incomplete outcome data addressed? Yes Quote: “Forty patients enrolled in the study,
3 were excluded (8%) before the code was
opened”
Comment: The reasons were given but not by
group as the code was not broken. It is felt
not to be a source of bias
Free of selective reporting? Yes Comment: Clinical and mycological eradica-
tion (culture).
Free of other biases? Unclear No information on funding except all study
drugs supplied by Pfizer
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Meunier 1990b
Methods Randomised, parallel group study conducted in Belgium. Patient, carer not blind, unclear
whether assessor blind. Unclear information on withdrawals. No information about funding.
No dates for recruitment period
Participants Patients with mixed cancer. 42 patients evaluated.
Interventions 2 groups. Ketoconazole tablets 200 mg every 8 hours. Nystatin 1000000 U suspension every
8 hours. Mean duration of ketoconazole was 13 days, nystatin 10 days, with maximum of 23
days for both groups
Outcomes Clinical eradication of oropharyngeal candidiasis or oral thrush. Microbiological eradication
of pathogen (culture)
Notes
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Quote: “Patients were randomly allocated to
one of the two arms of the study using a ran-
domisation list”
Allocation concealment? Yes Quote: “The allocations were placed in sealed
envelopes numbered sequentially”
Quote: “Randomisation was done by one of
the investigators following the numerical or-
der”
Blinding of participants and carers? No Comment: tablets and suspension.
Blinding of outcome assessors? Unclear No information.
Incomplete outcome data addressed? Unclear Comment: 2 ketoconazole patients had early
discontinuation. All other patients were
treated for at least 10 days. In nystatin group
3 patients died. It is unclear whether these pa-
tients were included in the 42 or not
Free of selective reporting? Yes Comment: Clinical and mycological eradica-
tion(culture) .
Free of other biases? Unclear No information about funding.
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Oude 2004
Methods Randomised, parallel group, multicentre study conducted in Europe. Patients, carer and
assessor not blind, but mycological assessment. No withdrawals. No information on funding.
Recruitment between January 1992 and October 1997
Participants Adults with mixed cancer. 279 randomised but only 252 eligible and evaluated. Of the 27
patients 23 were not eligible and 4 had no CRF
Interventions 2 groups. Fluconazole capsules 100 mg per day for 10 days. Itraconazole capsules 200 mg per
day for 15 days
Outcomes Clinical and mycological eradication at day 15 (culture). Evaluated at days 3, 7, 10, 15 and
post-treatment assessment at day 42
Notes It is surprising that the study was not published for 7 years
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: “....patients were randomised....”.
Allocation concealment? Unclear No information.
Blinding of participants and carers? No Quote: “An open multicentre comparative
study....”.
Blinding of outcome assessors? No Quote: “An open multicentre comparative
study....”.
Incomplete outcome data addressed? Yes Comment: 4 patients hadnoCRFbut unclear
which group however we felt this was unlikely
to cause bias
Free of selective reporting? Yes Comment: Clinical and mycological eradica-
tion (culture) .
Free of other biases? Unclear No information on funding.
Shechtman 1984
Methods Randomised, parallel group study conducted in USA. Patient, carer and assessor blind. Clear
explanation of withdrawals. Funding from pharmaceutical company and charity. No dates
for recruitment period
Participants Adults with mixed cancer. 16 enrolled, 13 completed.
Interventions 2 groups, placebo versus clotrimazole 10 mg troche of clotrimazole 5 times/day (dissolving
for 15 to 30 minutes). Duration 48 hours to 4 weeks
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Shechtman 1984 (Continued)
Outcomes Clinical improvement with intention-to-treat analysis. Mycological not eradicated (culture).
Unclear when assessment made
Notes
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: “Eight patients were assigned by ran-
dom allocation....”
Allocation concealment? Unclear No information given.
Blinding of participants and carers? Yes Quote “....double blind clinical trial ....”.
Quote: “Neither the patient, microbiologist,
physician or nurse know whether the patients
were receiving placebo or clotrimazole”
Blinding of outcome assessors? Yes Quote “....double blind clinical trial....”.
Quote: “Neither the patient, microbiologist,
physician or nurse know whether the patients
were receiving placebo or clotrimazole”
Incomplete outcome data addressed? Yes Comment: 4 patients lost to follow-up (25%)
, 2 in each group with known reasons
Free of selective reporting? Yes Comment: Clinical and mycological eradica-
tion (culture).
Free of other biases? Unclear Industry funding and charity grant. Miles
pharmaceuticals provided “coded” drugs
Studena 1995
Methods Randomised, parallel group study conducted in Slovac Republic. Patient, carer, not blind,
unclear if assessor blind. Funding unclear. Recruitment 1.5.1992 until 1.5.1994
Participants Adults with mixed cancer. 53 randomised and completed.
Interventions 2 groups. Fluconazole 10 days 100 mg OD or itraconazole 100 mg BID 15 days
Outcomes Clinical and mycological eradication (culture) at 15 and 42 days
Notes
Risk of bias
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Studena 1995 (Continued)
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: “Patients were randomised....”.
Allocation concealment? Unclear Comment: No information given.
Blinding of participants and carers? No Comment: Drugs taken over different peri-
ods.
Blinding of outcome assessors? Unclear Comment: No information given.
Incomplete outcome data addressed? Yes Quote: “All cancer patients with neutrophil
count more than 500 hospitalised at the Na-
tionalCancerCentre clinical of the PostGrad-
uate Medical School and Medical Faculty
from 1.5.1992 to 1.5.1994 (53 patients) were
randomised.”
Comment: Analysis on 53 patients, so no
drop outs.
Free of selective reporting? Yes Comment: Clinical and mycological eradica-
tion (culture).
Free of other biases? Unclear No information about funding.
Yap 1979
Methods Randomised, parallel group study conducted in USA. Patient, carer, assessor blind. No clear
explanation of withdrawals. Pharaceutical and government funding. No recruitment dates
given
Participants Adults with mixed cancer. 56 patients, 60 episodes enrolled. 52 episodes, 48 patients com-
pleted
Interventions 2 groups. 10 mg versus 50 mg troche clotrimazole, for 14 days
Outcomes Clinical and mycological eradication (culture).
Unclear when assessment made.
Notes As number of episodes 60 nearly same as number of patients so episodes used in analysis
Risk of bias
Item Authors’ judgement Description
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Yap 1979 (Continued)
Adequate sequence generation? Unclear Quote: “A randomised double blind trial....”.
Quote: “....a randomised double blind tech-
nique was used to divide the patients into two
groups....”
Allocation concealment? Unclear No information given.
Blinding of participants and carers? Yes Quote: “A randomised double blind trial....”.
Blinding of outcome assessors? Yes Quote: “A randomised double blind trial....”.
Incomplete outcome data addressed? Unclear Quote: “56 cancer patients with 60 episodes
of oropharyngeal candidiasis were entered
into he study between September 1976 and
September 1977”
Quote: “Eight patients 8 episodes were con-
sidered inevaluable”. Of the remaining 48 pa-
tients there were 52 episodes of infection
Comment: We don’t know which group these
patients were in.
Free of selective reporting? Yes Comment: Clinical and mycological eradica-
tion (culture).
Free of other biases? No Quote: “If there was no clinical improvement
after 5 days or the patients condition necessi-
tated the start of systemic antifungal therapy,
administration of the troches was discontin-
ued”
Possible bias due to episodes rather than pa-
tients and data not independent
Comment: Pharmaceutical and government
funding.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Anaissie 1996 Patients with invasive candidiasis from 2 or more body sites were included (fluconazole versus amphotericin B)
Benhamou 1991 Patients with and without fungal infection were included in study (ketoconazole versus placebo)
Bourhis 2004 Empirical treatment of suspected fungal infections in neutropenic patients with fever
Conrad 1990 AIDS and malignancy patients. Data not presented separately (nystatin versus clotrimazole)
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(Continued)
Domenge 1999 Abstract, insufficient information (fluconazole versus amphotericin)
Fleming 2001 Patients had5different conditions for entry including invasive fungal infection (amphotericinB versusAmBisome)
Holst 1984 Not RCT (natamycin versus nystatin).
Jorgensen 2006 Note on Walsh 2004, which is excluded (caspofungin versus amphotericin)
Kostiala 1982 Episodes (85) not patients (53) (clotrimazole versus chlorhexidine)
Lake 1996 Esophageal candidiasis present for entry into the study (fluconazole versus amphotericin B)
Lefebvre 2002 Not all patients had oral candidiasis at the start of study (fluconazole versus amphotericin B)
Subira 2004 All patients had to be hospitalised for neutropenic fever, but did not necessarily have oral candidiasis at entry to
study (amphotericin B)
Urabe 1990 Unclear if RCT (amphotericin B).
Verweij 1994 Patients had histologically proved systemic mycosis for entry into the study (amphotericin B versus amphotericin
B plus 5-flucytosine)
Walsh 2002 Not RCT (voriconazole).
Walsh 2004 Empirical therapy only treating patients with infection (caspofungin versus amphotericin)
Yamaguchi 2006 Patients who did not have cancer were included (translated from Japanese)
RCT = randomised controlled trial
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D A T A A N D A N A L Y S E S
Comparison 1. All studies
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Clinical: eradication of oral
candidiasis
10 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 Drug absorbed
(ketoconazole) versus placebo
1 56 Risk Ratio (M-H, Fixed, 95% CI) 3.61 [1.47, 8.88]
1.2 Drug partially absorbed
(clotrimazole) versus placebo
1 13 Risk Ratio (M-H, Fixed, 95% CI) 3.43 [0.51, 22.94]
1.3 Drug absorbed versus
drug absorbed (fluconazole
versus itraconazole)
2 293 Risk Ratio (M-H, Fixed, 95% CI) 1.14 [1.00, 1.30]
1.4 Drug absorbed versus
drug absorbed (fluconazole
versus ketoconazole)
1 37 Risk Ratio (M-H, Fixed, 95% CI) 1.02 [0.72, 1.42]
1.5 Drug absorbed
(fluconazole/ketoconazole)
versus drug not absorbed
(amphotericin/nystatin)
3 207 Risk Ratio (M-H, Fixed, 95% CI) 1.29 [1.09, 1.52]
1.6 Drug partially absorbed
versus drug partially absorbed
(clotrimazole 50 mg versus 10
mg)
1 52 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.90, 1.11]
1.7 Drug partially absorbed
versus drug partially absorbed
(miconazole 50 mg tablet
versus 500mg gel)
1 282 Risk Ratio (M-H, Fixed, 95% CI) 1.16 [0.91, 1.47]
2 Mycological: eradication of oral
candidiasis
9 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 Drug absorbed
(ketoconazole) versus placebo
1 47 Risk Ratio (M-H, Fixed, 95% CI) 5.09 [0.73, 35.49]
2.2 Drug partially absorbed
(clotrimazole) versus placebo
1 13 Risk Ratio (M-H, Fixed, 95% CI) 6.13 [0.38, 99.14]
2.3 Drug absorbed versus
drug absorbed (fluconazole
versus itraconazole)
2 291 Risk Ratio (M-H, Fixed, 95% CI) 1.17 [1.04, 1.33]
2.4 Drug absorbed versus
drug absorbed (fluconazole
versus ketoconazole)
1 37 Risk Ratio (M-H, Fixed, 95% CI) 0.95 [0.52, 1.72]
2.5 Drug absorbed
(fluconazole/ketoconazole)
versus not absorbed
(amphotericin/nystatin)
3 189 Risk Ratio (M-H, Fixed, 95% CI) 1.82 [1.28, 2.57]
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2.6 Drug partially absorbed
versus partially absorbed
(clotrimazole 50 mg versus 10
mg)
1 52 Risk Ratio (M-H, Fixed, 95% CI) 2.0 [1.11, 3.60]
Analysis 1.1. Comparison 1 All studies, Outcome 1 Clinical: eradication of oral candidiasis.
Review: Interventions for treating oral candidiasis for patients with cancer receiving treatment
Comparison: 1 All studies
Outcome: 1 Clinical: eradication of oral candidiasis
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Drug absorbed (ketoconazole) versus placebo
Hughes 1983 26/36 4/20 100.0 % 3.61 [ 1.47, 8.88 ]
Subtotal (95% CI) 36 20 100.0 % 3.61 [ 1.47, 8.88 ]
Total events: 26 (Treatment), 4 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.80 (P = 0.0052)
2 Drug partially absorbed (clotrimazole) versus placebo
Shechtman 1984 4/7 1/6 100.0 % 3.43 [ 0.51, 22.94 ]
Subtotal (95% CI) 7 6 100.0 % 3.43 [ 0.51, 22.94 ]
Total events: 4 (Treatment), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.27 (P = 0.20)
3 Drug absorbed versus drug absorbed (fluconazole versus itraconazole)
Oude 2004 93/122 78/118 78.0 % 1.15 [ 0.98, 1.36 ]
Studena 1995 25/27 22/26 22.0 % 1.09 [ 0.90, 1.33 ]
Subtotal (95% CI) 149 144 100.0 % 1.14 [ 1.00, 1.30 ]
Total events: 118 (Treatment), 100 (Control)
Heterogeneity: Chi2 = 0.19, df = 1 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 1.91 (P = 0.056)
4 Drug absorbed versus drug absorbed (fluconazole versus ketoconazole)
Meunier 1990a 15/19 14/18 100.0 % 1.02 [ 0.72, 1.42 ]
Subtotal (95% CI) 19 18 100.0 % 1.02 [ 0.72, 1.42 ]
Total events: 15 (Treatment), 14 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.09 (P = 0.93)
5 Drug absorbed (fluconazole/ketoconazole) versus drug not absorbed (amphotericin/nystatin)
Finlay 1996 27/37 16/36 24.3 % 1.64 [ 1.08, 2.49 ]
Flynn 1995 49/50 30/42 48.8 % 1.37 [ 1.13, 1.67 ]
0.1 0.2 0.5 1 2 5 10
Favours control Favours treatment
(Continued . . . )
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(. . . Continued)
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Meunier 1990b 13/18 21/24 26.9 % 0.83 [ 0.60, 1.14 ]
Subtotal (95% CI) 105 102 100.0 % 1.29 [ 1.09, 1.52 ]
Total events: 89 (Treatment), 67 (Control)
Heterogeneity: Chi2 = 8.98, df = 2 (P = 0.01); I2 =78%
Test for overall effect: Z = 3.02 (P = 0.0026)
6 Drug partially absorbed versus drug partially absorbed (clotrimazole 50 mg versus 10 mg)
Yap 1979 25/26 25/26 100.0 % 1.00 [ 0.90, 1.11 ]
Subtotal (95% CI) 26 26 100.0 % 1.00 [ 0.90, 1.11 ]
Total events: 25 (Treatment), 25 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
7 Drug partially absorbed versus drug partially absorbed (miconazole 50 mg tablet versus 500mg gel)
Bensadoun 2008 74/141 64/141 100.0 % 1.16 [ 0.91, 1.47 ]
Subtotal (95% CI) 141 141 100.0 % 1.16 [ 0.91, 1.47 ]
Total events: 74 (Treatment), 64 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.19 (P = 0.24)
0.1 0.2 0.5 1 2 5 10
Favours control Favours treatment
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Analysis 1.2. Comparison 1 All studies, Outcome 2 Mycological: eradication of oral candidiasis.
Review: Interventions for treating oral candidiasis for patients with cancer receiving treatment
Comparison: 1 All studies
Outcome: 2 Mycological: eradication of oral candidiasis
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Drug absorbed (ketoconazole) versus placebo
Hughes 1983 12/33 1/14 100.0 % 5.09 [ 0.73, 35.49 ]
Subtotal (95% CI) 33 14 100.0 % 5.09 [ 0.73, 35.49 ]
Total events: 12 (Treatment), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.64 (P = 0.10)
2 Drug partially absorbed (clotrimazole) versus placebo
Shechtman 1984 3/7 0/6 100.0 % 6.13 [ 0.38, 99.14 ]
Subtotal (95% CI) 7 6 100.0 % 6.13 [ 0.38, 99.14 ]
Total events: 3 (Treatment), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.28 (P = 0.20)
3 Drug absorbed versus drug absorbed (fluconazole versus itraconazole)
Oude 2004 101/121 86/117 83.5 % 1.14 [ 0.99, 1.30 ]
Studena 1995 24/27 17/26 16.5 % 1.36 [ 1.00, 1.85 ]
Subtotal (95% CI) 148 143 100.0 % 1.17 [ 1.04, 1.33 ]
Total events: 125 (Treatment), 103 (Control)
Heterogeneity: Chi2 = 1.09, df = 1 (P = 0.30); I2 =9%
Test for overall effect: Z = 2.53 (P = 0.012)
4 Drug absorbed versus drug absorbed (fluconazole versus ketoconazole)
Meunier 1990a 10/19 10/18 100.0 % 0.95 [ 0.52, 1.72 ]
Subtotal (95% CI) 19 18 100.0 % 0.95 [ 0.52, 1.72 ]
Total events: 10 (Treatment), 10 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.18 (P = 0.86)
5 Drug absorbed (fluconazole/ketoconazole) versus not absorbed (amphotericin/nystatin)
Finlay 1996 17/37 11/36 36.7 % 1.50 [ 0.82, 2.75 ]
Flynn 1995 29/41 5/33 18.2 % 4.67 [ 2.03, 10.72 ]
Meunier 1990b 11/18 16/24 45.1 % 0.92 [ 0.58, 1.46 ]
Subtotal (95% CI) 96 93 100.0 % 1.82 [ 1.28, 2.57 ]
Total events: 57 (Treatment), 32 (Control)
Heterogeneity: Chi2 = 13.65, df = 2 (P = 0.001); I2 =85%
Test for overall effect: Z = 3.35 (P = 0.00081)
0.1 0.2 0.5 1 2 5 10
Favours control Favours treatment
(Continued . . . )
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(. . . Continued)
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
6 Drug partially absorbed versus partially absorbed (clotrimazole 50 mg versus 10 mg)
Yap 1979 18/26 9/26 100.0 % 2.00 [ 1.11, 3.60 ]
Subtotal (95% CI) 26 26 100.0 % 2.00 [ 1.11, 3.60 ]
Total events: 18 (Treatment), 9 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.31 (P = 0.021)
0.1 0.2 0.5 1 2 5 10
Favours control Favours treatment
A P P E N D I C E S
Appendix 1. Cochrane Oral Health Group Trials Register; Cochrane Pain, Palliative & Supportive
Care Group Trials Register search strategy
((neoplasm* OR leukemia OR leukaemia OR leukaemia OR lymphoma* OR plasmacytoma OR “histiocytosis malignant” OR retic-
uloendotheliosis OR “sarcoma mast cell” OR “Letterer Siwe disease” OR “immunoproliferative small intestine disease” OR “Hodgkin
disease” OR “histiocytosis malignant” OR “bone marrow transplant*” OR cancer* Or tumor* OR tumour* OR malignan* OR neu-
tropeni* OR carcino* OR adenocarcinoma* OR radioth* OR radiat* OR radiochemo* OR irradiat* OR chemo*) AND (stomatitis
OR “Stevens Johnson syndrome” OR “candidiasis oral” OR mucositis OR (oral AND (cand* OR mucos* OR fung*)) OR mycosis
OR mycotic OR thrush))
Appendix 2. The Cochrane Central Register of Controlled Trials (CENTRAL) search strategy
Search strategy for the Cochrane Library
1. Exp NEOPLASMS
2. Exp LEUKEMIA
3. Exp LYMPHOMA
4. Exp RADIOTHERAPY
5. Exp BONE MARROW TRANSPLANTATION
6. neoplasm* or cancer* or carcino* or malignan*
7. leukemi* or leukaemia*
8. tumour* or tumor*
9. neutropeni*
10. adenocarcinoma*
11. lymphoma*
12. (radioth* or radiat* or irradiat* or radiochemo*)
13. (bone next marrow next transplant*)
14. chemo* or radiochemo*
15. (#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14)
16. Exp STOMATITIS
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17. MUCOSITIS
18. CANDIDIASIS ORAL
19. stomatitis
20. (stevens next johnson next syndrome)
21. mucositis
22. oral near cand*
23. mouth near cand*
24. oral and fung*
25. mouth and fung*
26. (mycosis or mycotic or thrush)
27. #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26
28. #15 AND #27
Appendix 3. MEDLINE via OVID search strategy
1. exp NEOPLASMS/
2. exp LEUKEMIA/
3. exp LYMPHOMA/
4. exp RADIOTHERAPY/
5. Bone Marrow Transplantation/
6. neoplasm$.mp.
7. cancer$.mp.
8. (leukaemi$ or leukemi$).mp.
9. (tumour$ or tumor$).mp.
10. malignan$.mp.
11. neutropeni$.mp.
12. carcino$.mp.
13. adenocarcinoma$.mp.
14. lymphoma$.mp.
15. (radioth$ or radiat$ or irradiat$).mp.
16. (bone adj marrow adj5 transplant$).mp.
17. chemo$.mp.
18. or/1-17
19. exp STOMATITIS/
20. Candidiasis, Oral/
21. stomatitis.mp.
22. mucositis.mp.
23. (oral and cand$).mp.
24. (oral adj6 mucos$).mp.
25. (oral and fung$).mp.
26. (mycosis or mycotic).mp.
27. or/19-26
28. 18 and 27
The above search was linked to the Cochrane Highly Sensitive Search Strategy (CHSSS) for identifying randomized trials in MEDLINE:
sensitivity maximising version (2009 revision) as referenced in Chapter 6.4.11.1 and detailed in box 6.4.c of The Cochrane Handbook for
Systematic Reviews of Interventions, Version 5.0.2 [updated September 2009].
1. randomized controlled trial.pt.
2. controlled clinical trial.pt.
3. randomized.ab.
4. placebo.ab.
5. drug therapy.fs.
6. randomly.ab.
29Interventions for treating oral candidiasis for patients with cancer receiving treatment (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
7. trial.ab.
8. groups.ab.
9. or/1-8
10. exp animals/ not humans.sh.
11. 9 not 10
Appendix 4. EMBASE SS via OVID search strategy
1. exp NEOPLASM/
2. exp LEUKEMIA/
3. exp LYMPHOMA/
4. exp RADIOTHERAPY/
5. exp bone marrow transplantation/
6. (neoplasm$or cancer$ or leukemi$or leukaemi$ or tumour$ or tumor$ ormalignan$ or neutropeni$ or carcino$ or adenocarcinoma$
or lymphoma$).mp.
7. (radioth$ or radiat$ or irradiat$ or radiochemo$).mp.
8. (bone marrow adj3 transplant$).mp.
9. chemo$.mp.
10. or/1-9
11. exp Stomatitis/
12. Thrush/
13. (stomatitis or mucositis or (oral and candid$) or (oral adj4 mucositis) or (oral and fung$) or mycosis or mycotic or thrush).mp.
14. or/11-13
15. 10 and 14
The above search was linked to the Cochrane Oral Health Group filter for identifying randomized controlled trials in EMBASE:
1. random$.ti,ab.
2. factorial$.ti,ab.
3. (crossover$ or cross over$ or cross-over$).ti,ab.
4. placebo$.ti,ab.
5. (doubl$ adj blind$).ti,ab.
6. (singl$ adj blind$).ti,ab.
7. assign$.ti,ab.
8. allocat$.ti,ab.
9. volunteer$.ti,ab.
10. CROSSOVER PROCEDURE.sh.
11. DOUBLE-BLIND PROCEDURE.sh.
12. RANDOMIZED CONTROLLED TRIAL.sh.
13. SINGLE BLIND PROCEDURE.sh.
14. or/1-13
15. ANIMAL/ or NONHUMAN/ or ANIMAL EXPERIMENT/
16. HUMAN/
17. 16 and 15
18. 15 not 17
19. 14 not 18
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Appendix 5. CINAHLvia EBSCO search strategy
S1 (MH “Neoplasms+”)
S2 (MH “Leukemia+”)
S3 (MH “Lymphoma+”)
S4 (MH “Radiotherapy+”)
S5 (MH “Bone Marrow Transplantation”)
S6 neoplasm*
S7 cancer*
S8 (leukemi* or leukaemi*)
S9 (tumour* or tumor*)
S10 malignan*
S11 neutropeni*
S12 carcino*
S13 adenocarcinoma*
S14 lymphoma*
S15 (radioth* or radiat* or irradiat*)
S16 (bone N1 marrow N5 transplant*)
S17 chemo*
S18 S1 or S2 or S3 or S4 or S5 or S6 or S7 or S8 or S9 or S10 or S11 or
S12 or S13 or S14 or S15 or S16 or S17
S19 MH “Stomatitis+”
S20 MH “Candidiasis, Oral”
S21 stomatitis
S22 mucositis
S23 (oral and cand*)
S24 (oral N6 mucos*)
S25 (oral and fung*)
S26 (mycosis or mycotic)
S27 S19 or S20 or S21 or S22 or S23 or S24 or S25 or S26
S28 S18 AND S27
The above search was linked to the Cochrane Oral Health Group search strategy for identifying randomized controlled trials in
CINAHL:
S1 MH Random Assignment or MH Single-blind Studies or MH Double-blind Studies or MH Triple-blind Studies or MH
Crossover design or MH Factorial Design
S2 TI (“multicentre study” or “multicenter study” or “multi-centre study” or “multi-center study”) or AB (“multicentre study”
or “multicenter study” or “multi-centre study” or “multi-center study”) or SU (“multicentre study” or “multicenter study” or “multi-
centre study” or “multi-center study”)
S3 TI random* or AB random*
S4 AB “latin square” or TI “latin square”
S5 TI (crossover or cross-over) or AB (crossover or cross-over) or SU (crossover or cross-over)
S6 MH Placebos
S7 AB (singl* or doubl* or trebl* or tripl*) or TI (singl* or doubl* or trebl* or tripl*)
S8 TI blind* or AB mask* or AB blind* or TI mask*
S9 S7 and S8
S10 TI Placebo* or AB Placebo* or SU Placebo*
S11 MH Clinical Trials
S12 TI (Clinical AND Trial) or AB (Clinical AND Trial) or SU (Clinical AND Trial)
S13 S1 or S2 or S3 or S4 or S5 or S6 or S9 or S10 or S11 or S12
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Appendix 6. CANCERLIT (PubMed Cancer Subset) search strategy
((neoplasm* OR leukemia OR leukaemia OR leukaemia OR lymphoma* OR plasmacytoma OR “histiocytosis malignant” OR retic-
uloendotheliosis OR “sarcoma mast cell” OR “Letterer Siwe disease” OR “immunoproliferative small intestine disease” OR “Hodgkin
disease” OR “histiocytosis malignant” OR “bone marrow transplant*” OR cancer* Or tumor* OR tumour* OR malignan* OR neu-
tropeni* OR carcino* OR adenocarcinoma* OR radioth* OR radiat* OR radiochemo* OR irradiat* OR chemotherap*) AND (stom-
atitis OR “Stevens Johnson syndrome” OR “candidiasis oral” OR mucositis OR (oral AND (candid* OR mucos* OR fung*)) OR
mycosis OR mycotic OR thrush))
The above search strategy was linked to the Cochrane Highly Sensitive Search Strategy (CHSSS) for identifying randomized trials in
MEDLINE via PubMed: sensitivity maximising version (2009 revision) as referenced in Chapter 6.4.11.1 and detailed in box 6.4.a of
The Cochrane Handbook for Systematic Reviews of Interventions, Version 5.0.2 [updated September 2009].
(randomized controlled trial [pt] OR controlled clinical trial [pt] OR randomized controlled trials [mh] OR random allocation [mh]
OR double-blind method [mh] OR single-blind method [mh] OR clinical trial [pt] OR clinical trials [mh] OR (“clinical trial” [tw]
OR ((singl* [tw] OR doubl* [tw] OR trebl* [tw] OR tripl* [tw]) AND (mask* [tw] OR blind* [tw] )) OR (placebos [mh] OR placebo*
[tw] OR random* [tw] OR research design [mh:noexp]) NOT (animals [mh] NOT human [mh]))
Appendix 7. OpenSIGLE search strategy
N.B. SIGLE is now provided through OpenSIGLE: http://opensigle.inist.fr/
SIGLE no longer supports complex searching, so a series of keyword searches was performed as below:
cancer AND mucositis AND oral
leukemia AND mucositis AND oral
leukaemia AND mucositis AND oral
carcinoma AND mucositis AND oral
lymphoma AND mucositis AND oral
tumour AND mucositis AND oral
tumor AND mucositis AND oral
cancer AND candidiasis AND oral
leukemia AND candidiasis AND oral
leukaemia AND candidiasis AND oral
carcinoma AND candidiasis AND oral
lymphoma AND candidiasis AND oral
tumour AND candidiasis AND oral
tumor AND candidiasis AND oral
Appendix 8. LILACS via the Virtual Health Library search strategy
(www.bireme.org)
Mh NEOPLASMS OR Tw neoplasm$ OR Tw cancer$ OR Tw carcinoma$ OR Tw tumour$ OR Tw tumor$ OR Tw malignan$
OR Tw carcino$ OR Tw nuetropeni$ OR Tw adenocarcinoma$ OR Mh leukemia OR Tw leukaemia$ OR Tw leukemi$ OR Tw
lymphoma$ OR Tw “bone marrow transplantation” OR Tw “bone marrow transplant$” OR Tw radiotherapy OR Tw radioth$ OR
Tw radiat$ OR Tw irradiat$ OR Tw radiochemo$ OR Tw chemo$
AND
Mh stomatitis OR Tw stomatitis OR Mh Candidiasis-Oral OR Tw “oral candidiasis” OR (Tw candida$ AND (Tw mouth OR Tw
oral)) OR Tw mucositis OR ((Tw oral OR mouth) AND Tw fung$) OR (Tw oral AND Tw candidiasis$)
The above search was linked to the Brazilian Cochrane Center search strategy for identifying randomized controlled trials in LILACs:
((Pt randomized controlled trial OR Pt controlled clinical trial ORMh randomized controlled trials ORMh random allocation ORMh
double-blind method ORMh single-blind method) ANDNOT (Ct animals AND NOT (Ct human and Ct animal)) OR (Pt clinical
trial OR Ex E05.318.760.535$ OR (Tw clin$ AND (Tw trial$ OR Tw ensa$ OR Tw estud$ OR Tw experim$ OR Tw investiga$))
OR ((Tw singl$ OR Tw simple$ OR Tw doubl$ OR Tw doble$ OR Tw duplo$ OR Tw trebl$ OR Tw trip$) AND (Tw blind$ OR
Tw cego$ OR Tw ciego$ OR Tw mask$ OR Tw mascar$)) ORMh placebos OR Tw placebo$ OR (Tw random$ OR Tw randon$ OR
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Tw casual$ OR Tw acaso$ OR Tw azar OR Tw aleator$) OR Mh research design) AND NOT (Ct animals AND NOT (Ct human
and Ct animals)) OR (Ct comparative study OR Ex E05.337$ ORMh follow-up studies ORMh prospective studies OR Tw control$
OR Tw prospectiv$ OR Tw volunt$ OR Tw volunteer$) AND NOT (Ct animals AND NOT (Ct human and Ct animals)))
WH A T ’ S N E W
Last assessed as up-to-date: 31 May 2010.
Date Event Description
9 June 2010 New search has been performed Substantive amendment. Updated search found 1 new in-
cluded trial and 1 excluded study. New methodology
9 June 2010 New citation required but conclusions have not changed New authorship.
H I S T O R Y
Protocol first published: Issue 1, 2000
Review first published: Issue 1, 2002
Date Event Description
5 February 2007 New citation required but conclusions have not changed Substantive amendment. An updated search in 2006
has found one more trial to include in this review, and
seven more excluded studies. This update has updated
references to other Cochrane reviews however the results
and conclusions remain unchanged
C O N T R I B U T I O N S O F A U T H O R S
Jan Clarkson (JC) and Helen Worthington (HW) wrote the protocol and review. HW co-ordinated the review and wrote the letters to
authors. JC and HW independently and in duplicate assessed the eligibility of trials, extracted data and assessed the quality of the trials.
HW conducted the statistical analysis which was interpreted by JC and HW. Tasneem Khalid provided advice on the interventions and
Stefan Meyer and Martin McCabe provided input on the cancer treatments and the assessment of the candidiasis.
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D E C L A R A T I O N S O F I N T E R E S T
None known.
S O U R C E S O F S U P P O R T
Internal sources
• Scottish Executive Health Department, UK.
• University of Dundee, UK.
• University of Manchester, UK.
• Scottish Council for Postgraduate Medical and Dental Education, UK.
• Manchester Biomedical Research Centre, University of Manchester, UK.
• Cancer Research UK, UK.
• Teenage Cancer Trust, UK.
External sources
• NIDCR grant ref 1 DE016950-01, USA.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Antifungal Agents [pharmacokinetics; ∗therapeutic use]; Candidiasis, Oral [∗drug therapy; metabolism]; Gastrointestinal Tract
[metabolism]; Neoplasms [∗therapy]; Randomized Controlled Trials as Topic
MeSH check words
Humans
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